Aquestive Therapeutics
NASDAQ: AQSTWarren, US · Delaware corporation · 150 employees on LinkedIn · 1 known investors
Find your way into Aquestive Therapeutics
389 people in our graph share verified history with the Aquestive Therapeutics team — schools, employers, funds. One of them is your warm intro.
Zhenyu Tangunlockedknows Keith J Kendall · together at Hewlett-Packard Financial Services (overlapped)
×6knows the team · via Hewlett-Packard Financial Services
×2knows the team · via NYU Stern School of Business
×2knows the team · via Seton Hall University
knows the team · via Xerox Corporation
Aquestive Therapeutics develops and commercializes oral film drug formulations and other novel delivery systems for treatments in neurology, psychiatry, and emergency care, operating manufacturing facilities in Indiana that produce both licensed pharmaceutical products and proprietary candidates for regulated markets including the U.S., EU, and Australia.
Founders & leadership
KJ
Keith J KendallinChief Executive Officer2014–2022Keith Kendall is Chief Executive Officer of Aquestive Therapeutics, where he brings extensive experience in business operations, strategy, and capital markets. He has held financial leadership roles including CFO and has served on public, private, and non-profit boards in the U.S. and U.K., with experience in mergers, acquisitions, and public offerings.
AM
A. Mark ShobelChief Operating Officer
TW
Theresa WoodinSVP2006–2022
PB
Peter BoydVice President, Value Delivery
DB
Daniel BarberinChief Executive OfficerDaniel Barber is Chief Operating Officer at Aquestive Therapeutics, a pharmaceutical company developing oral film formulations and novel drug delivery systems. He has held leadership roles in pharmaceutical product development, corporate and business development, and operations.
JT
John T MaxwellinChief Financial Officer2017–2020He has held senior finance roles managing mergers and acquisitions, capital markets transactions including IPOs and debt recapitalizations, and operations in life sciences and healthcare sectors.
GB
Gregory BrownNamed on SEC filing
DB
Douglas BrattonNamed on SEC filing
JC
John CochranNamed on SEC filing
SC
Santo CostaNamed on SEC filing
JS
James S ScibettaNamed on SEC filing
Investors · 1
Reported raises · per SEC filings
Form D private placements$9.1M disclosed across 1 round · 2018
▶$9.1MraisedMay 2018 · 15 investors · PharmaceuticalsRule 506(b)
▶$9.1MraisedMay 2018 · 15 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Gregory BrownDirector
- Keith J KendallExecutive Officer, Director
- A. Mark ShobelExecutive Officer, Director
- Theresa WoodExecutive Officer
- Douglas BrattonDirector
- John CochranDirector
- Santo CostaDirector
- Peter BoydExecutive Officer
- James S ScibettaDirector
- Daniel BarberExecutive Officer
- John T MaxwellExecutive Officer
- Offering amount
- $9.1M
- Amount sold
- $9.1M
- Minimum investment
- $100
- First sale
- Apr 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed events$367.5Mvaluation at IPOJul 2018 · $15.00/share · 424B4
filing ↗Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
In the news
Four investor events are planned for September by Aquestive Therapeutics. Two talks will be available to watch online.stocktitan.net · Sep 2026
Aquestive Therapeutics to Participate in Upcoming September Investor Conferences | The Manila Timesmanilatimes.net · Sep 2026
Aquestive (AQST) Q2 2026 Earnings Call Transcript - AOLaol.com · Aug 2026Frequently asked questions
- What does Aquestive Therapeutics do?
- Aquestive Therapeutics develops and commercializes oral film drug formulations and other novel delivery systems for treatments in neurology, psychiatry, and emergency care, operating manufacturing facilities in Indiana that produce both licensed pharmaceutical products and proprietary candidates for regulated markets including the U.S., EU, and Australia.
- Who are Aquestive Therapeutics's investors?
- Aquestive Therapeutics's investors include Oaktree.
- How much funding has Aquestive Therapeutics raised?
- Aquestive Therapeutics has disclosed $9.1M raised across 1 round.
- Where is Aquestive Therapeutics headquartered?
- Aquestive Therapeutics is headquartered in Warren, US.